Dr. Monk on the emergence of NaPi2b as a target in ovarian cancer

Bradley J. Monk, MD, FACS, discusses the emergence and utility of NaPi2b as a target in ovarian cancer.

Bradley J. Monk, MD, FACS, FACOG, Professor, Division of Gynecologic Oncology, Arizona Oncology (US Oncology Network), University of Arizona College of Medicine, Creighton University School of Medicine at St. Joseph’s Hospital, Medical Director, Gynecologic Program , US Oncology Research Network, Co-Director, GOG Partners, discusses the emergence and utility of NaPi2b as a target in ovarian cancer.

NaPi2b, a sodium-dependent phosphate transporter, says Monk. NaPi2b is targeted by the investigational antibody-drug conjugate upifitamab rilsodotin (UpRi), which is a humanized monoclonal antibody with a specific linker and auristatin payload. The agent also has a high drug-to-antibody ratio, Monk explains. Additionally, DolaLock auristatin is controlled by a spectator effect that allows the payload to be selectively released into the tumor, Monk adds.

Overall, research has been done to optimize the dosage of UpRi so that patients can continue treatment for a long time, Monk continues. The FDA granted UpRi expedited designation in August 2020 for the treatment of patients with high-grade platinum-resistant serous ovarian cancer who have received up to 3 prior lines of systemic therapy or 4 prior lines of systemic therapy, regardless of their platinum status. In addition, the first UPLIFT phase 1/2 human study (NCT03319628) is currently recruiting patients with platinum-resistant ovarian cancer or metastatic non-small cell lung cancer to assess the safety and efficacy of UpRi in tumors likely to express NaPi2b, Monk concludes.

Comments are closed.